Case Study
A Krystal Clear Vision: Develop Genetic Medicines for Patients with Rare Diseases
Krystal Biotech is a Pittsburgh‑based biotechnology company dedicated to developing genetic medicines for patients with rare and often underserved diseases. With limited treatment options available for many rare conditions, the company focuses on delivering innovative, redosable gene therapies designed to provide lasting benefit. Krystal’s platform is built on a non‑integrating, replication‑defective herpes simplex virus type‑1 vector, enabling repeated dosing without modifying patient DNA. Its flagship therapy, beremagene geperpavec, targets dystrophic epidermolysis bullosa, a severe and incurable genetic skin disorder. Through this approach, Krystal Biotech aims to transform care for patients with rare diseases by combining scientific innovation with patient‑centered treatment solutions.
